Skip to main content

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.02
+1.72 (0.72%)
AAPL  260.19
+0.71 (0.27%)
AMD  242.88
+6.15 (2.60%)
BAC  53.22
+0.02 (0.04%)
GOOG  339.65
+1.12 (0.33%)
META  709.15
-7.35 (-1.03%)
MSFT  425.33
-4.96 (-1.15%)
NVDA  187.91
-3.22 (-1.68%)
ORCL  168.03
+3.45 (2.10%)
TSLA  417.02
-13.39 (-3.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.